Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

被引：0

作者：

Pleyer, Lisa ^{[1
,2
]}

Burgstaller, Sonja ^{[3
]}

Stauder, Reinhard ^{[4
]}

Girschikofsky, Michael ^{[5
]}

Linkesch, Werner ^{[6
]}

Pfeilstoecker, Michael ^{[7
]}

Autzinger, Eva Maria ^{[8
]}

Tinchon, Christoph ^{[9
]}

Sliwa, Thamer ^{[7
]}

Lang, Alois ^{[10
]}

Sperr, Wolfgang R. ^{[11
]}

Geissler, Dietmar ^{[12
]}

Krippl, Peter ^{[13
]}

Voskova, Daniela ^{[14
]}

Rossmann, Dieter H. ^{[15
]}

Schlick, Konstantin ^{[16
]}

Thaler, Josef ^{[3
]}

Halter, Britta ^{[4
]}

Machherndl-Spandl, Sigrid ^{[5
]}

Theiler, Georg ^{[17
]}

Valent, Peter ^{[11
]}

Eckmuellner, Otto ^{[18
]}

Greil, Richard ^{[1
,19
]}

机构：

[1] Paracelsus Med Univ Salzburg, Salzburg, Austria

[2] Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria

[3] Klinikum Wels Grieskirchen, Wels, Austria

[4] Med Univ Innsbruck, A-6020 Innsbruck, Austria

[5] Elisabethinen Hosp, Linz, Austria

[6] Med Univ Graz, Graz, Austria

[7] Hanusch Hosp, Vienna, Austria

[8] Wilhelminenspital Stadt Wien, Vienna, Austria

[9] LKH Leoben, Leoben, Austria

[10] LKH Rankweil, Rankweil, Austria

[11] Med Univ Vienna, Vienna, Austria

[12] Klinikum Klagenfurt, Klagenfurt, Austria

[13] LKH Furstenfeld, Furstenfeld, Austria

[14] Gen Hosp Linz, Linz, Austria

[15] Hosp Steyr, Steyr, Austria

[16] PMU, Salzburg, Austria

[17] LKH Hartberg, Hartberg, Austria

[18] Forest Growth, Vienna, Austria

[19] Salzburg Canc Res Inst, Salzburg, Austria

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Impact of race on outcomes in intermediate-risk acute myeloid leukemia
Ivy Elizabeth Abraham
Anand Ashwin Patel
Heidy Wang
John Patrick Galvin
Olga Frankfurt
Li Liu
Irum Khan
Cancer Causes & Control, 2021, 32 : 705 - 712
[2] Impact of race on outcomes in intermediate-risk acute myeloid leukemia
Abraham, Ivy Elizabeth
Patel, Anand Ashwin
Wang, Heidy
Galvin, John Patrick
Frankfurt, Olga
Liu, Li
Khan, Irum
CANCER CAUSES & CONTROL, 2021, 32 (07) : 705 - 712
[3] IMPACT OF MOLECULAR MARKERS ON THE OUTCOME OF ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS
Hoyos, M.
Brunet, S.
Tormo, M.
Ribera, J. M.
Nomdedeu, J.
Esteve, J.
Llorente, A.
Gallardo, D.
Queipo de Llano, M. P.
Duarte, R.
Heras, I.
Besalduch, J.
Bargay, J.
Marti, J. M.
Pedro, C.
Gonzalez, J.
Font, L.
Pratcorona, M.
Oriol, A.
Sierra, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 268 - 269
[4] Azacitidine in a patient with newly diagnosed acute myeloid leukemia and poor risk cytogenetics: Outcomes of prolonged therapy
Pappa, Vasiliki
Girkas, Konstantinos
Sambani, Constantina
Pagageorgiou, Sotiris
Tsirigiotis, Panagiotis
Karvounis, Kiki
Stathopoulou, Evangelia
Economopoulos, Theofanis
Dimitriadis, George
Dervenoulas, Ioannis
LEUKEMIA RESEARCH, 2012, 36 (04) : E78 - E80
[5] 5′-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics
Diaz-Santa, Johana
Rodriguez-Romanos, Rocio
Coll, Rosa
Osca, Gemma
Pratcorona, Marta
Gonzalez-Bartulos, Marta
Garrido, Ana
Angona, Anna
Talarn, Carme
Tormo, Mar
Arnan, Montserrat
Vives, Susanna
Salamero, Olga
Tuset, Esperanza
Lloveras, Natalia
Diez, Isabel
Zamora, Lurdes
Bargay, Joan
Sampol, Antonia
Cruz, David
Vila, Jordi
Sitges, Marta
Garcia, Antoni
Vall-Llovera, Ferran
Esteve, Jordi
Sierra, Jorge
Gallardo, David
EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (06) : 755 - 764
[6] TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
Chou, Wen-Chien
Chou, Sheng-Chieh
Liu, Chieh-Yu
Chen, Chien-Yuan
Hou, Hsin-An
Kuo, Yuan-Yeh
Lee, Ming-Cheng
Ko, Bor-Sheng
Tang, Jih-Luh
Yao, Ming
Tsay, Woei
Wu, Shang-Ju
Huang, Shang-Yi
Hsu, Szu-Chun
Chen, Yao-Chang
Chang, Yi-Chang
Kuo, Yi-Yi
Kuo, Kuan-Ting
Lee, Fen-Yu
Liu, Ming-Chi
Liu, Chia-Wen
Tseng, Mei-Hsuan
Huang, Chi-Fei
Tien, Hwei-Fang
BLOOD, 2011, 118 (14) : 3803 - 3810
[7] A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within Intermediate-Risk Acute Myeloid Leukemia
Hu, Xiaoxia
Huang, Aijie
Chen, Qi
Zhang, Ying
Liu, Lixia
Wang, Chengcheng
Zhang, Weiping
Yang, Jianmin
BLOOD, 2019, 134
[8] Impact of Race on Outcomes in Intermediate Risk Acute Myeloid Leukemia
Abraham, Ivy
Patel, Anand Ashwin
Zhang, Yanyu
Liu, Li C.
Frankfurt, Olga
Khan, Irum
BLOOD, 2018, 132
[9] The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics
J How
J Sykes
M D Minden
V Gupta
K W L Yee
A D Schimmer
A C Schuh
S Kamel-Reid
J M Brandwein
Blood Cancer Journal, 2013, 3 : e116 - e116
[10] Intermediate-risk acute myeloid leukemia therapy: current and future
Doehner, Konstanze
Paschka, Peter
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 34 - 43

← 1 2 3 4 5 →